WallStreetZenWallStreetZen

NASDAQ: IMRX
Immuneering Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMRX

Based on 4 analysts offering 12 month price targets for Immuneering Corp

Min Forecast
$9.00+139.36%
Avg Forecast
$13.25+252.39%
Max Forecast
$21.00+458.51%

Should I buy or sell IMRX stock?

Based on 4 analysts offering ratings for Immuneering Corp.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMRX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IMRX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their IMRX stock forecasts and price targets.

IMRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-14
lockedlocked$00.00+00.00%2025-06-18
lockedlocked$00.00+00.00%2025-06-18
lockedlocked$00.00+00.00%2025-05-07

1 of 1

Forecast return on equity

Is IMRX forecast to generate an efficient return?

Company
-269.23%
Industry
119.29%
Market
-46.52%
IMRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMRX forecast to generate an efficient return on assets?

Company
-194.49%
Industry
46.9%
IMRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMRX earnings per share forecast

What is IMRX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.66
Avg 2 year Forecast
-$1.64
Avg 3 year Forecast
-$2.23

IMRX revenue forecast

What is IMRX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$21.7M
Avg 2 year Forecast
$108.7M
Avg 3 year Forecast
$239.7M

IMRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMRX$3.04$13.25+335.86%Strong Buy
SPRO$1.98N/AN/A
LIMN$4.12N/AN/A
ZNTL$1.48$7.25+389.86%Buy
ZURA$1.72$11.25+554.07%Strong Buy
View Top Biotech Stocks

Immuneering Stock Forecast FAQ

Is Immuneering Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: IMRX) stock is to Strong Buy IMRX stock.

Out of 4 analysts, 1 (25%) are recommending IMRX as a Strong Buy, 3 (75%) are recommending IMRX as a Buy, 0 (0%) are recommending IMRX as a Hold, 0 (0%) are recommending IMRX as a Sell, and 0 (0%) are recommending IMRX as a Strong Sell.

If you're new to stock investing, here's how to buy Immuneering stock.

What is IMRX's earnings growth forecast for 2025-2027?

(NASDAQ: IMRX) Immuneering's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Immuneering's earnings in 2025 is -$62,128,864.On average, 4 Wall Street analysts forecast IMRX's earnings for 2025 to be -$60,289,336, with the lowest IMRX earnings forecast at -$76,632,830, and the highest IMRX earnings forecast at -$50,483,239. On average, 4 Wall Street analysts forecast IMRX's earnings for 2026 to be -$59,381,364, with the lowest IMRX earnings forecast at -$84,986,172, and the highest IMRX earnings forecast at -$21,064,949.

In 2027, IMRX is forecast to generate -$80,991,096 in earnings, with the lowest earnings forecast at -$98,060,968 and the highest earnings forecast at -$63,921,224.

What is IMRX's revenue growth forecast for 2028-2030?

(NASDAQ: IMRX) Immuneering's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.

Immuneering's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast IMRX's revenue for 2028 to be $788,301,225, with the lowest IMRX revenue forecast at $527,350,094, and the highest IMRX revenue forecast at $1,049,252,357. On average, 1 Wall Street analysts forecast IMRX's revenue for 2029 to be $3,946,045,986, with the lowest IMRX revenue forecast at $3,946,045,986, and the highest IMRX revenue forecast at $3,946,045,986.

In 2030, IMRX is forecast to generate $8,705,998,006 in revenue, with the lowest revenue forecast at $8,705,998,006 and the highest revenue forecast at $8,705,998,006.

What is IMRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IMRX) forecast ROA is -194.49%, which is lower than the forecast US Biotechnology industry average of 46.9%.

What is IMRX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year IMRX price target, the average IMRX price target is $13.25, with the highest IMRX stock price forecast at $21.00 and the lowest IMRX stock price forecast at $9.00.

On average, Wall Street analysts predict that Immuneering's share price could reach $13.25 by Aug 14, 2026. The average Immuneering stock price prediction forecasts a potential upside of 335.86% from the current IMRX share price of $3.04.

What is IMRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IMRX) Immuneering's current Earnings Per Share (EPS) is -$1.90. On average, analysts forecast that IMRX's EPS will be -$1.66 for 2025, with the lowest EPS forecast at -$2.11, and the highest EPS forecast at -$1.39. On average, analysts forecast that IMRX's EPS will be -$1.64 for 2026, with the lowest EPS forecast at -$2.34, and the highest EPS forecast at -$0.58. In 2027, IMRX's EPS is forecast to hit -$2.23 (min: -$2.70, max: -$1.76).

What is IMRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IMRX) forecast ROE is -269.23%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.